Scilex Holding Company’s Post

Join TechBBQ and FBV at Nordic IPO + Stock Market Day the 10th of September 2024. Meet Henrik Blou, CEO at Gubra who speaks about the IPO and his experiences running a listed company. The company is based near Copenhagen offers expert preclinical research services enabling pharmaceutical and biotech companies to advance their drug development pipeline. At Nordic IPO + Stock Market Day you can meet and connect with investors, the ecosystem around the stock market and listed companies – and learn from others: 👉 Why I consider to list my company? 👉 Why IPOs are sometimes wise? 👉 What does the investors look for in IPOs and listed SMEs? 👉 When should you consider to list your company? Our event sponsors: Danske Bank, DI - Dansk Industri, Nasdaq, Spotlight Stock Market , ComplyLog, a Euronext company, Pressemeddelelser Via Ritzau, Computershare , ABG Sundal Collier, Cision, HC Andersen Capital, Nordea & Danish Business Angels - DanBAN Avnit Singh, Michael Bak, Henriette Kinnunen, Katrine Hoff, Thomas Black-Petersen, Sine Linderstrøm, Lars Sandahl Sørensen, Carsten Borring #dkbiz #stockmarket #ipo #techbbq

Checkout this useful guide from RxBridge and prepare your 📑 checklist when buying a pharmacy 💊

The serum proteome market has changed rapidly in FY23 Q4.  Christian Lautenschläger, PhD, PhD and I conducted an analysis of SomaLogic's FY23 Q3, and FY23 full year revenue reports. Through the recent merger, it will be interesting to observe the business strategy and revenue growth of SomaLogic in FY24.  #LifeSciences #FinancialInsights #GrowthStrategies #FutureOutlook #SerumProteomeMarket 

The MedTech industry waits for no-one! Back in the office after a fantastic break in Antibes, France; and back with some industry insights. Huge acquisitions and FDA/CE Mark approvals for market leaders; Start-ups and scale ups securing significant funding and gaining approvals and an important CEO announcement. Keep on making a difference MedTech! #medtech #insidemedtech #medtechnews #medtechinsights

Evolus rings the Nasdaq closing bell after celebrating its first profitable quarterly earnings call since 2018. Below, I break down several sources and press releases with David Moatazedi, covering: ->Introduction to Evolus ->Key milestones and achievements since IPO ->Words from their leadership ->Financial highlights: Revenue, R&D Investment, Net Profit & Loss, EPS ->Future plans for the brand Evolus’ competitive edge against market leaders in the toxin market stems from its pricing strategy and focus on younger consumers. They are known by many for their bold and unique Marketing. The company positions Jeuveau (branded as "Newtox") as a more affordable alternative, priced approximately 20-25% lower than Botox which has proven to be a key driver for its growth. Together, this resonates well with a younger demographic interested in cosmetic procedures but looking for cost-effective options whilst maintaining quality. This appeal has not only helped increase adoption but also enabled Evolus to carve out a niche in an industry dominated by legacy brands. Enjoy.

📣 23𝐚𝐧𝐝𝐌𝐞'𝐬 𝐬𝐭𝐫𝐮𝐠𝐠𝐥𝐞 𝐭𝐨 𝐩𝐫𝐨𝐟𝐢𝐭 𝐥𝐞𝐝 𝐭𝐨 𝐚 98% 𝐝𝐫𝐨𝐩 𝐢𝐧 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧! Once a pioneering DNA-testing company, 23andMe is navigating a challenging landscape, witnessing a staggering 98% drop in valuation and facing a Nasdaq delisting threat due to its sub-$1 stock. CEO Anne Wojcicki's ambitious vision to transform the company into a comprehensive healthcare provider is encountering hurdles, including financial setbacks and hurdles in drug development. 💰 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐚𝐥 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐚𝐧𝐝 𝐀𝐦𝐛𝐢𝐭𝐢𝐨𝐮𝐬 𝐆𝐨𝐚𝐥𝐬: despite Anne Wojcicki's commitment to reshaping 23andMe's future, financial challenges loom large. Early-stage drug programs face difficulties in attracting investor partners, raising questions about the feasibility of Wojcicki's vision. 🧬 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: 23andMe's core challenge lies in the nature of its DNA-testing business - customers typically take the test only once, and the results often lack significant health impact. Despite these obstacles, Wojcicki remained determined to leverage genetic information to empower consumers to manage their healthcare. 🔐 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 𝐏𝐢𝐯𝐨𝐭: The pivot towards subscriptions, with offerings like "23andMe+" and "Total Health," aimed to establish a recurring revenue stream. However, projections fell short, with less than half the projected subscribers, posing additional challenges for the company's financial sustainability. More at https://lnkd.in/dQQhjtVw #dnatesting #23andme #nasdaq #challenges #digitalhealth

The Good, The Bad, The Ugly: Biotech Edition (#JPM24 Special) The good, bad, and ugly stories from biotech and pharma. #JPM24 Quick Hits Longshot; 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚’s ambitions plans into 2030 🎯 https://lnkd.in/gE5q4HqW Bumps in the road; 𝐂𝐑𝐈𝐒𝐏𝐑’s (slow-burn) deal-hunt 🏹 https://lnkd.in/gVbBBybE Tubthumping; 𝐌𝐨𝐝𝐞𝐫𝐧𝐚’s fall (and planned rise) 🏋️♂️ https://lnkd.in/gKU7RPXj Tall order; 𝐁𝐢𝐨𝐌𝐚𝐫𝐢𝐧’s new CEO priorities 🚀 https://lnkd.in/gXBY2MKd Shallow valley; 𝐌𝐞𝐫𝐜𝐤’s future growth away from Keytruda 🏞️ https://lnkd.in/gXwBDYH6 Buy Now, Pay Later; 𝐛𝐥𝐮𝐞𝐛𝐢𝐫𝐝 justifies GT price premium 💰 https://lnkd.in/gFm_BiZY Bosh-off, ADC-on; 𝐏𝐟𝐢𝐳𝐞𝐫 hungry for more 💼 https://lnkd.in/gJSXHBqs A Plump Deal; 𝐓𝐚𝐤𝐞𝐝𝐚 details 𝐍𝐢𝐦𝐛𝐮𝐬 acquisition 🤝 https://lnkd.in/gt5ZCwnT Eating fruits; 𝐏𝐚𝐜𝐁𝐢𝐨 showcases impressive growth 📈 https://lnkd.in/gQVDprm8 Slide into my (M&A) DMs; 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 looking to buy 🤑 https://lnkd.in/gXydCdTn The Good Foreshadowing?; FDA hints at 𝐒𝐚𝐫𝐞𝐩𝐭𝐚 GT label expansion 😯 https://lnkd.in/gj2PDV6d Not a dry eye in the house; 𝐀𝐥𝐜𝐨𝐧's takeover pays off 🤩 https://lnkd.in/gv55fGHu The Bad Anti-Deal; 𝐂𝐨𝐡𝐞𝐫𝐮𝐬 cuts 𝐉𝐮𝐧𝐬𝐡𝐢 partnership ✂️ https://lnkd.in/ghNJVTUc Implosion; 𝐂4 lays off 30% 😢 https://lnkd.in/gzeSHXrv The Ugly Unsafe approach; 𝐆𝐢𝐥𝐞𝐚𝐝 allegedly delayed safer med 😓 https://lnkd.in/gM4UMxKJ Get off my lawn; 𝐍𝐨𝐯𝐚𝐫𝐭𝐢𝐬 may sue generic competitor ⚖️ https://lnkd.in/gbziTRhP Powered by Science 2 Sales - helping scientists land awesome jobs in sales and business development.  Free 30 minute consult :) https://lnkd.in/gFdQXWba #biotechnews #pharmanews #goodbaduglybiotech

📣 We are pleased to announce that Cuprina Holdings, a Singapore-based biomedical and biotechnology company, is preparing for its IPO and inviting investors to participate. 📌 Access to the IPO is available through NVB for a seamless investment experience. The company specializes in the development and commercialization of innovative products for chronic wound care, as well as cosmeceuticals for the healthcare and beauty sectors. Deal Terms: ◽ Security type: Common Shares ◾ Offering type: IPO ◽Expected IPO date: Late August 2024 ◾Listing exchange: NASDAQ ◽Ticker symbol: CUPR ◾Offering size: $15 million ◽Expected price per share: $4 ◾Minimum investment: $25,000 ◽Brokerage fee: 5% ◾Application start date: August 12, 2024 📈 Cuprina Holdings is poised to make a significant impact in the global healthcare market. Stay tuned for more updates. #IPO #Biotechnology #BiomedicalResearch #CuprinaHoldings #Healthcare #Innovation #NASDAQ

Another week, another round of hot deals and exciting news in the world of M&A! We've handpicked a selection of last week's closed deals for you. For more details and to discover all the deals in the sector that interests you (and much more!): https://lnkd.in/enTvMFuU News Week 13-24 🚀 Add-on MoxeXM (Hesse / DEU), a specialist in software and platform development for customer experience management (CXM), acquires Feeddex and 5-sterrenspecialist. This double acquisition, supported by Pride Capital Partners, enables MoxeXM to expand its CXM offering in Europe. 🚀 Acquisition Accession Capital Partners invests in WAWRZASZEK ISS (WISS) (Silesia / POL), a manufacturer of specialized fire and emergency vehicles. ACP will support the company's growth in partnership with founder Piotr Wawrzaszek and his family. 🚀 Acquisition Siparex acquires a majority stake in Capron Podologie (c. €23M in revenue in 2023, Bourgogne-Franche-Comté / FRA), a manufacturer of equipment for podiatrists and chiropodists. This transaction, led by the Siparex Midcap 4 fund, will enable the company to accelerate its international expansion. 🚀 Exit Ingersoll Rand ($5.5 billion of revenue in 2022, Leinster / IRL), an industrial company specializing in the design and manufacture of compressors, blowers, pumps, vacuum products, fluid transfer products, and material handling equipment, has acquired ILC Dover (Delaware / USA), a company specializing in the design and production of flexible containment solutions for the biopharmaceutical, pharmaceutical, medical device, and aerospace markets. With this acquisition, Ingersoll will expand its customer base and develop in high-growth end markets such as life sciences. Notably, ILC Dover's investors included Linden Capital Partners and New Mountain Capital, who thus contributed to its success. Don't miss the latest trends and news from the world of investment funds by following our page. #InvestmentFunds #PrivateEquity #MergerandAcquisition

🌟 Big week for IPOs! 🌟 🚀 Tonight, allotment for Bansal Wire Industries and Emcure Pharmaceuticals is expected. 📢Looking ahead, Ola Electric Mobility's Mainboard IPO announcement could be coming soon! 🔔Don't miss out on the SME action either! Ganesh Green Bharat and Effwa Infra & Research are in their second day. Stay tuned for more updates! 📈📊 #stockmarket #investing #stockmarketnews #marketwatch #finance #stockmarketupdates #financialfreedom #investmentopportunities